VACCINE for coronavirus treatment expected to be available by end of 2020, says WHO

India's first indigenous COVID-19 vaccine Covaxin initiated phase-1 clinical trials across the country on 15 July 2020.

AS India has started a human trial for a COVID-19 vaccine, UK based famed Oxford University, China and Russia have claimed to have passed the human trial stage successfully causing no after-effect on the persons opted for the trials. POTUS Donald Trump has tweeted Biotech firm Moderna Inc’s experimental vaccine for COVID-19 showed it is safe and provoked immune responses in all 45 health volunteers. In India, about 7 companies are making vaccines for coronavirus, but Bharat Biotech and ICMR are leading the race with Covaxin whose human trial started on Monday, July 20 at AIIMS Delhi. A total of 100 persons have volunteered to participate in this trial. Overall, 375 people will be part of the human trial for this vaccine which will be tested in 12 different hospitals across the country.  More persons are needed for the ongoing trials.AIIMS Director Dr Randeep Guleria is optimistic about results in three months. The World Health Organization is also hopeful that one or two vaccines may be available by the end of this year saying there are some countries and a few companies that are ahead of others. The AIIMS Ethics Committee has okayed starting a human clinical trial of the indigenously developed Covaxin. Healthy volunteers having no comorbid conditions and without a history of Covid-19, aged more than 18 years and less than 55 years, would be eligible to participate in the randomised, double-blind, placebo-controlled clinical trial,” Dr Sanjay Rai, professor at the centre for community medicine at AIIMS, said. In phase I, the vaccine will be tested on 375 volunteers. India is one of the largest vaccine producers in the world having no dearth of  scientists. Covaxin, developed by Bharat Biotech in collaboration with ICMR and NIV, Pune, will be tested on more than 1,100 people in phase 1 and 2 clinical trials. The Drugs Controller General of India (DCGI) has permitted two vaccines the one developed by the Bharat Biotech International Limited and another one by ZydusCadila Healthcare Ltd the first and second phase of human clinical trials. More persons  are needed for the ongoing trials.

Leave a Reply

Your email address will not be published. Required fields are marked *